Teva Pharmaceuticals (NYSE:TEVA) and Xenon Pharmaceuticals (NSDQ:XENE) said this week that the Phase II study of a topical post-herpetic neuralgia treatment did not meet its primary or secondary endpoints.
The small-molecule inhibitor, TV-45070, was licensed by Xenon to Teva in December 2012.
The Phase II trial enrolled 300 patients and randomized them to receive 4% TV-45070, 8% TV-45070 or placebo twice per day. The primary endpoint was the change of average daily pain scores between baseline and 4 weeks following treatment.
The study’s secondary endpoints were the percentage of patients with more than 30% and greater than 50% improvement in pain scores, quality of life measures and adverse events measurements.
“While these results are disappointing for us from a scientific perspective and for patients needing new therapies to treat chronic neuropathic pain, Xenon remains focused on advancing its pipeline of neurology-related development candidates, with multiple programs anticipated to enter clinical development in 2017,” Xenon president & CEO Simon Pimstone said in prepared remarks.
